The Consequences of GBA Deficiency in the Autophagy–Lysosome System in Parkinson’s Disease Associated with GBA

GBA gene variants were the first genetic risk factor for Parkinson’s disease. GBA encodes the lysosomal enzyme glucocerebrosidase (GBA), which is involved in sphingolipid metabolism. GBA exhibits a complex physiological function that includes not only the degradation of its substrate glucosylceramide but also the metabolism of other sphingolipids and additional lipids such as cholesterol, particularly when glucocerebrosidase activity is deficient. In the context of Parkinson’s disease associated with GBA, the loss of GBA activity has been associated with the accumulation of α-synuclein species. In recent years, several hypotheses have proposed alternative and complementary pathological mechanisms to explain why lysosomal enzyme mutations lead to α-synuclein accumulation and become important risk factors in Parkinson’s disease etiology. Classically, loss of GBA activity has been linked to a dysfunctional autophagy–lysosome system and to a subsequent decrease in autophagy-dependent α-synuclein turnover; however, several other pathological mechanisms underlying GBA-associated parkinsonism have been proposed. This review summarizes and discusses the different hypotheses with a special focus on autophagy-dependent mechanisms, as well as autophagy-independent mechanisms, where the role of other players such as sphingolipids, cholesterol and other GBA-related proteins make important contributions to Parkinson’s disease pathogenesis.

[1]  M. Vila,et al.  Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology , 2022, npj Parkinson's Disease.

[2]  A. Schapira,et al.  Glucocerebrosidase mutations and Parkinson disease , 2022, Journal of Neural Transmission.

[3]  T. Noma,et al.  Redefining GBA gene structure unveils the ability of Cap-independent, IRES-dependent gene regulation , 2022, Communications Biology.

[4]  R. Krüger,et al.  GBA-associated PD: chances and obstacles for targeted treatment strategies , 2022, Journal of Neural Transmission.

[5]  A. Schapira,et al.  GBA Variants and Parkinson Disease: Mechanisms and Treatments , 2022, Cells.

[6]  Ori J. Lieberman,et al.  Mutant glucocerebrosidase impairs α-synuclein degradation by blockade of chaperone-mediated autophagy. , 2022, Science advances.

[7]  N. Engedal,et al.  Measuring Autophagic Cargo Flux with Keima-Based Probes. , 2022, Methods in molecular biology.

[8]  R. Pellegrino,et al.  Drug-Induced Lysosomal Impairment Is Associated with the Release of Extracellular Vesicles Carrying Autophagy Markers , 2021, International journal of molecular sciences.

[9]  B. Nordén,et al.  Orientation of α-Synuclein at Negatively Charged Lipid Vesicles: Linear Dichroism Reveals Time-Dependent Changes in Helix Binding Mode , 2021, Journal of the American Chemical Society.

[10]  A. Cuervo,et al.  Autophagy and the hallmarks of aging , 2021, Ageing Research Reviews.

[11]  D. Wesson,et al.  Heterozygous GBA D409V and ATP13a2 mutations do not exacerbate pathological α-synuclein spread in the prodromal preformed fibrils model in young mice , 2021, Neurobiology of Disease.

[12]  K. Setchell,et al.  Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease , 2021, Cells.

[13]  A. Ballabio,et al.  Autophagy in major human diseases , 2021, The EMBO journal.

[14]  E. Gazit,et al.  Glucosylceramide Associated with Gaucher Disease Forms Amyloid-like Twisted Ribbon Fibrils That Induce α-Synuclein Aggregation , 2021, ACS nano.

[15]  T. Lamark,et al.  Mechanisms of Selective Autophagy. , 2021, Annual review of cell and developmental biology.

[16]  Monika Kandebo,et al.  Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse model , 2021, PloS one.

[17]  N. Krogan,et al.  Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome , 2021, Cell.

[18]  Elias T. Zambidis,et al.  Elevated glucosylsphingosine in Gaucher disease induced pluripotent stem cell neurons deregulates lysosomal compartment through mammalian target of rapamycin complex 1 , 2021, Stem cells translational medicine.

[19]  M. van Eijk,et al.  GCase and LIMP2 Abnormalities in the Liver of Niemann Pick Type C Mice , 2021, International journal of molecular sciences.

[20]  D. Galasko,et al.  The Mutation Matters: CSF Profiles of GCase, Sphingolipids, α‐Synuclein in PDGBA , 2021, Movement disorders : official journal of the Movement Disorder Society.

[21]  D. D. Di Monte,et al.  GBA Mutations Influence the Release and Pathological Effects of Small Extracellular Vesicles from Fibroblasts of Patients with Parkinson’s Disease , 2021, International journal of molecular sciences.

[22]  Jennifer C. Lee,et al.  Membrane Interactions of α-Synuclein Probed by Neutrons and Photons. , 2021, Accounts of chemical research.

[23]  Mark R. Marten,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 , 2021, Autophagy.

[24]  Frederik Ravnkilde Marlet,et al.  The interplay between Glucocerebrosidase, α-synuclein and lipids in human models of Parkinson's disease. , 2020, Biophysical chemistry.

[25]  M. Martínez-Vicente,et al.  The Emerging Role of the Lysosome in Parkinson’s Disease , 2020, Cells.

[26]  N. Mizushima,et al.  Autophagy in Human Diseases. , 2020, The New England journal of medicine.

[27]  M. Tittgemeyer,et al.  GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes , 2020, Movement disorders : official journal of the Movement Disorder Society.

[28]  M. van Eijk,et al.  Lyso-glycosphingolipids: presence and consequences , 2020, Essays in biochemistry.

[29]  A. Desautels,et al.  GBA variants in REM sleep behavior disorder , 2020, Neurology.

[30]  P. Saftig,et al.  Cholesterol Handling in Lysosomes and Beyond. , 2020, Trends in cell biology.

[31]  A. Schapira,et al.  Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons , 2020, Human molecular genetics.

[32]  G. Knott,et al.  The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration , 2020, Proceedings of the National Academy of Sciences.

[33]  A. Schapira,et al.  Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation , 2020, Neurobiology of Disease.

[34]  A. Singleton,et al.  Genetics of Parkinson's disease: An introspection of its journey towards precision medicine , 2020, Neurobiology of Disease.

[35]  D. Berg,et al.  Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha‐Synuclein Profiles , 2020, Movement disorders : official journal of the Movement Disorder Society.

[36]  E. Holzbaur,et al.  Neuronal autophagy declines substantially with age and is rescued by overexpression of WIPI2 , 2019, Autophagy.

[37]  Sonja W. Scholz,et al.  Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies , 2019, The Lancet Neurology.

[38]  A. Ballabio,et al.  Lysosomes as dynamic regulators of cell and organismal homeostasis , 2019, Nature Reviews Molecular Cell Biology.

[39]  L. Casalis,et al.  GM1 Ganglioside role in the interaction of Alpha-synuclein with lipid membranes: Morphology and structure. , 2019, Biophysical chemistry.

[40]  M. Lipinski,et al.  mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cells , 2019, Disease Models & Mechanisms.

[41]  S. Grinstein,et al.  Lysosomal integral membrane protein-2 (LIMP-2/SCARB2) is involved in lysosomal cholesterol export , 2019, Nature Communications.

[42]  M. Stamelou,et al.  Autophagy dysfunction in peripheral blood mononuclear cells of Parkinson’s disease patients , 2019, Neuroscience Letters.

[43]  A. Cuervo,et al.  Proteome-wide analysis of chaperone-mediated autophagy targeting motifs , 2019, PLoS biology.

[44]  Alan J. Thomas,et al.  Dementia with Lewy bodies: an update and outlook , 2019, Molecular Neurodegeneration.

[45]  M. Ivanova,et al.  Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases , 2019, PloS one.

[46]  G. Kroemer,et al.  Biological Functions of Autophagy Genes: A Disease Perspective , 2019, Cell.

[47]  Ottavio Arancio,et al.  Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations , 2018, Autophagy.

[48]  A. Mirelman,et al.  Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene. , 2018, Parkinsonism & related disorders.

[49]  Gennifer E. Merrihew,et al.  Glucocerebrosidase deficiency promotes protein aggregation through dysregulation of extracellular vesicles , 2018, PLoS genetics.

[50]  S. Linse,et al.  Ganglioside lipids accelerate α-synuclein amyloid formation , 2018, Biochimica et biophysica acta. Proteins and proteomics.

[51]  W. Wurst,et al.  Exosomal secretion of α-synuclein as protective mechanism after upstream blockage of macroautophagy , 2018, Cell Death & Disease.

[52]  J. Lanciego,et al.  Glucocerebrosidase Mutations and Synucleinopathies. Potential Role of Sterylglucosides and Relevance of Studying Both GBA1 and GBA2 Genes , 2018, Front. Neuroanat..

[53]  D. Krainc,et al.  Acid ceramidase inhibition ameliorates &agr;-synuclein accumulation upon loss of GBA1 function , 2018, Human molecular genetics.

[54]  Jennifer C. Lee,et al.  Effects of phosphatidylcholine membrane fluidity on the conformation and aggregation of N-terminally acetylated α-synuclein , 2018, The Journal of Biological Chemistry.

[55]  Joseph R. Mazzulli,et al.  Is Parkinson's disease a lysosomal disorder? , 2018, Brain : a journal of neurology.

[56]  N. Engedal,et al.  The Long-lived Protein Degradation Assay: an Efficient Method for Quantitative Determination of the Autophagic Flux of Endogenous Proteins in Adherent Cell Lines. , 2018, Bio-protocol.

[57]  V. Korolchuk,et al.  mTORC1 and Nutrient Homeostasis: The Central Role of the Lysosome , 2018, International journal of molecular sciences.

[58]  N. Hattori,et al.  Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice , 2018, Scientific Reports.

[59]  T. Dawson,et al.  α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism , 2018, Molecular Neurodegeneration.

[60]  Elsje G. Otten,et al.  mTORC1 as the main gateway to autophagy , 2017, Essays in biochemistry.

[61]  M. Ehlers,et al.  Lysosomal integral membrane protein-2 as a phospholipid receptor revealed by biophysical and cellular studies , 2017, Nature Communications.

[62]  A. Schapira,et al.  Insights into the structural biology of Gaucher disease , 2017, Experimental Neurology.

[63]  R. Krüger,et al.  The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p , 2017, Scientific Reports.

[64]  S. Chandra,et al.  Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease , 2017, The Journal of Neuroscience.

[65]  M. Nalls,et al.  A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci , 2017, Nature Genetics.

[66]  J. Kulisevsky,et al.  N370S‐GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.

[67]  K. Marder,et al.  Frequency of GBA Variants in Autopsy‐proven Multiple System Atrophy , 2017, Movement disorders clinical practice.

[68]  L. Karageorgos,et al.  Lipid composition of microdomains is altered in neuronopathic Gaucher disease sheep brain and spleen. , 2017, Molecular genetics and metabolism.

[69]  R. Zoncu,et al.  Lysosomal cholesterol activates mTORC1 via an SLC38A9–Niemann-Pick C1 signaling complex , 2017, Science.

[70]  David M. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[71]  M. Goedert,et al.  The Synucleinopathies: Twenty Years On , 2017, Journal of Parkinson's disease.

[72]  G. Schwarzmann,et al.  Lipids regulate the hydrolysis of membrane bound glucosylceramide by lysosomal β-glucocerebrosidase , 2017, Journal of Lipid Research.

[73]  J. Stirnemann,et al.  A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments , 2017, International journal of molecular sciences.

[74]  D. James Surmeier,et al.  Selective neuronal vulnerability in Parkinson disease , 2017, Nature Reviews Neuroscience.

[75]  F. Platt,et al.  The metabolism of glucocerebrosides - From 1965 to the present. , 2017, Molecular genetics and metabolism.

[76]  R. Barker,et al.  Dermal fibroblasts from patients with Parkinson's disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations. , 2017, F1000Research.

[77]  J. Volkmann,et al.  Parkinson disease , 2017, Nature Reviews Disease Primers.

[78]  A. Schapira,et al.  Glucocerebrosidase Mutations in Parkinson Disease. , 2017, Journal of Parkinson's Disease.

[79]  D. Klionsky,et al.  Autophagy wins the 2016 Nobel Prize in Physiology or Medicine: Breakthroughs in baker's yeast fuel advances in biomedical research , 2016, Proceedings of the National Academy of Sciences.

[80]  L. Partridge,et al.  A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin , 2016, The Journal of Neuroscience.

[81]  Haiqun Lin,et al.  Glucosylsphingosine is a key biomarker of Gaucher disease , 2016, American journal of hematology.

[82]  Roberto Zoncu,et al.  The Lysosome as a Regulatory Hub. , 2016, Annual review of cell and developmental biology.

[83]  T. Outeiro,et al.  Structure, function and toxicity of alpha‐synuclein: the Bermuda triangle in synucleinopathies , 2016, Journal of neurochemistry.

[84]  C. Mariani,et al.  Survival and dementia in GBA‐associated Parkinson's disease: The mutation matters , 2016, Annals of neurology.

[85]  R. Barker,et al.  Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's , 2016, Annals of neurology.

[86]  A. Schapira,et al.  Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease , 2016, Human molecular genetics.

[87]  L. Karageorgos,et al.  Glycosphingolipid analysis in a naturally occurring ovine model of acute neuronopathic Gaucher disease , 2016, Neurobiology of Disease.

[88]  D. Krainc,et al.  Characterization of the complex formed by β-glucocerebrosidase and the lysosomal integral membrane protein type-2 , 2016, Proceedings of the National Academy of Sciences.

[89]  S. Karlsson,et al.  Glucosylated cholesterol in mammalian cells and tissues: formation and degradation by multiple cellular β-glucosidases[S] , 2016, Journal of Lipid Research.

[90]  H. Christian,et al.  ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons , 2016, Stem cell reports.

[91]  P. Saftig,et al.  Mannose 6‐phosphate‐independent Lysosomal Sorting of LIMP‐2 , 2015, Traffic.

[92]  G. Halliday,et al.  Lysosomal‐associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[93]  Sarah C. Izen,et al.  Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons , 2015, Neurobiology of Disease.

[94]  Xiao-Min Wang,et al.  GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A , 2015, Autophagy.

[95]  M. Lipinski,et al.  Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells. , 2015, Human molecular genetics.

[96]  C. Ortiz Mellet,et al.  Pharmacological Chaperones and Coenzyme Q10 Treatment Improves Mutant β-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease , 2015, Scientific Reports.

[97]  B. Bembi,et al.  Role of LIMP‐2 in the intracellular trafficking of β‐glucosidase in different human cellular models , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[98]  A. Schapira Glucocerebrosidase and Parkinson disease: Recent advances , 2015, Molecular and Cellular Neuroscience.

[99]  M. Martínez-Vicente Autophagy in neurodegenerative diseases: From pathogenic dysfunction to therapeutic modulation. , 2015, Seminars in cell & developmental biology.

[100]  O. Isacson,et al.  Progressive decline of glucocerebrosidase in aging and Parkinson's disease , 2015, Annals of Clinical and Translational Neurology.

[101]  Frank Heinrich,et al.  Structural Features of Membrane-bound Glucocerebrosidase and α-Synuclein Probed by Neutron Reflectometry and Fluorescence Spectroscopy* , 2014, The Journal of Biological Chemistry.

[102]  J. Winkler,et al.  Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment , 2014, Autophagy.

[103]  G. Grabowski,et al.  The LIMP-2/SCARB2 Binding Motif on Acid β-Glucosidase , 2014, The Journal of Biological Chemistry.

[104]  E. Masliah,et al.  Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein , 2014, Nature Communications.

[105]  T. Sotnikova,et al.  Exogenous α-Synuclein Decreases Raft Partitioning of Cav2.2 Channels Inducing Dopamine Release , 2014, The Journal of Neuroscience.

[106]  Ying Sun,et al.  Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. , 2014, Human molecular genetics.

[107]  Chuong B. Do,et al.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.

[108]  S. Gygi,et al.  iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis , 2014, Nature Communications.

[109]  T. Foltynie,et al.  Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells , 2014, Brain : a journal of neurology.

[110]  C. Ferrarese,et al.  Reduced expression of the chaperone-mediated autophagy carrier hsc70 protein in lymphomonocytes of patients with Parkinson's disease , 2014, Brain Research.

[111]  Y. Hirabayashi,et al.  Cholesterol glucosylation is catalyzed by transglucosylation reaction of β-glucosidase 1. , 2013, Biochemical and biophysical research communications.

[112]  M. Wittstock,et al.  Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients , 2013, PloS one.

[113]  Peter Loppnau,et al.  Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36 , 2013, Nature.

[114]  M. Xilouri,et al.  LAMP2A as a therapeutic target in Parkinson disease , 2013, Autophagy.

[115]  Jennifer C. Lee,et al.  Saposin C protects glucocerebrosidase against α-synuclein inhibition. , 2013, Biochemistry.

[116]  M. Flint Beal,et al.  PGC-1α, mitochondrial dysfunction, and Huntington's disease. , 2013, Free radical biology & medicine.

[117]  A. Leftin,et al.  Solid-state ¹³C NMR reveals annealing of raft-like membranes containing cholesterol by the intrinsically disordered protein α-Synuclein. , 2013, Journal of molecular biology.

[118]  A. Schapira,et al.  Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease—Links to Parkinson’s Disease , 2013, Cell metabolism.

[119]  D. Sillence Glucosylceramide modulates endolysosomal pH in Gaucher disease. , 2013, Molecular genetics and metabolism.

[120]  M. Nalls,et al.  A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. , 2013, JAMA neurology.

[121]  A. Steven,et al.  α-Synuclein Oligomers with Broken Helical Conformation Form Lipoprotein Nanoparticles* , 2013, The Journal of Biological Chemistry.

[122]  M. Xilouri,et al.  Loss of β-Glucocerebrosidase Activity Does Not Affect Alpha-Synuclein Levels or Lysosomal Function in Neuronal Cells , 2013, PloS one.

[123]  A. Consiglio,et al.  Interplay of LRRK2 with chaperone-mediated autophagy , 2013, Nature Neuroscience.

[124]  M. Duchen,et al.  Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage , 2013, Neurochemistry International.

[125]  Jennifer C. Lee,et al.  Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. , 2013, Molecular genetics and metabolism.

[126]  T. Dawson,et al.  Development and Characterization of a New Parkinson's Disease Model Resulting from Impaired Autophagy , 2012, The Journal of Neuroscience.

[127]  S. Pang,et al.  Genetic analysis of the LAMP-2 gene promoter in patients with sporadic Parkinson's disease , 2012, Neuroscience Letters.

[128]  P. Saftig,et al.  A Critical Histidine Residue Within LIMP‐2 Mediates pH Sensitive Binding to Its Ligand β‐Glucocerebrosidase , 2012, Traffic.

[129]  A. Cuervo,et al.  Dietary lipids and aging compromise chaperone-mediated autophagy by similar mechanisms , 2012, Autophagy.

[130]  A. Schapira,et al.  A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[131]  P. Pollak,et al.  Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers , 2012, Neurology.

[132]  H. Gerritsen,et al.  Hyperacidification of Trans‐Golgi Network and Endo/Lysosomes in Melanocytes by Glucosylceramide‐Dependent V‐ATPase Activity , 2011, Traffic.

[133]  M. V. van Breemen,et al.  Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. , 2011, Blood.

[134]  J. Fantini,et al.  The fusogenic tilted peptide (67-78) of α-synuclein is a cholesterol binding domain. , 2011, Biochimica et biophysica acta.

[135]  R. Sidman,et al.  CNS expression of glucocerebrosidase corrects α-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy , 2011, Proceedings of the National Academy of Sciences.

[136]  Ying Sun,et al.  Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies , 2011, Cell.

[137]  Jennifer C. Lee,et al.  α-Synuclein Interacts with Glucocerebrosidase Providing a Molecular Link between Parkinson and Gaucher Diseases* , 2011, The Journal of Biological Chemistry.

[138]  Jifeng Li,et al.  Altered expression of autophagic genes in the peripheral leukocytes of patients with sporadic Parkinson's disease , 2011, Brain Research.

[139]  Chris Gardiner,et al.  Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission , 2011, Neurobiology of Disease.

[140]  Shaoxiao Wang,et al.  Defects in Very Long Chain Fatty Acid Synthesis Enhance Alpha-Synuclein Toxicity in a Yeast Model of Parkinson's Disease , 2011, PloS one.

[141]  I. Ferrer,et al.  Chaperone-mediated autophagy markers in Parkinson disease brains. , 2010, Archives of neurology.

[142]  E. Rhoades,et al.  Effects of curvature and composition on α-synuclein binding to lipid vesicles. , 2010, Biophysical journal.

[143]  A. Steven,et al.  Membrane Curvature Induction and Tubulation Are Common Features of Synucleins and Apolipoproteins* , 2010, The Journal of Biological Chemistry.

[144]  A. Manning-Boğ,et al.  Lysosomal Degradation of α-Synuclein in Vivo* , 2010, The Journal of Biological Chemistry.

[145]  E. Masliah,et al.  GFAP reactivity, apolipoprotein E redistribution and cholesterol reduction in human astrocytes treated with α-synuclein , 2010, Neuroscience Letters.

[146]  E. Sidransky,et al.  MUTATIONS IN GBA ARE ASSOCIATED WITH FAMILIAL PARKINSON DISEASE SUSCEPTIBILITY AND AGE AT ONSET , 2009, Neurology.

[147]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[148]  M. Nalls,et al.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. , 2009, The New England journal of medicine.

[149]  A. Singleton,et al.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. , 2009, Brain : a journal of neurology.

[150]  David Park,et al.  Abberant α-Synuclein Confers Toxicity to Neurons in Part through Inhibition of Chaperone-Mediated Autophagy , 2009, PloS one.

[151]  A. Brice,et al.  Parkinson's disease: from monogenic forms to genetic susceptibility factors. , 2009, Human molecular genetics.

[152]  A. Cuervo,et al.  Entering the lysosome through a transient gate by chaperone-mediated autophagy , 2008, Autophagy.

[153]  Kostas Vekrellis,et al.  Wild Type α-Synuclein Is Degraded by Chaperone-mediated Autophagy and Macroautophagy in Neuronal Cells* , 2008, Journal of Biological Chemistry.

[154]  M. Xilouri,et al.  Alpha-synuclein degradation by autophagic pathways: A potential key to Parkinson’s Disease pathogenesis , 2008, Autophagy.

[155]  A. Cuervo,et al.  The Chaperone-Mediated Autophagy Receptor Organizes in Dynamic Protein Complexes at the Lysosomal Membrane , 2008, Molecular and Cellular Biology.

[156]  Nir Giladi,et al.  Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset , 2008, Neurology.

[157]  K. Uchida,et al.  Aberrant molecular properties shared by familial Parkinson's disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1. , 2008, Human molecular genetics.

[158]  M. Langeveld,et al.  Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[159]  P. Gómez-Puertas,et al.  An evolutionary and structure‐based docking model for glucocerebrosidase–saposin C and glucocerebrosidase–substrate interactions—Relevance for Gaucher disease , 2008, Proteins.

[160]  P. Saftig,et al.  LIMP-2 Is a Receptor for Lysosomal Mannose-6-Phosphate-Independent Targeting of β-Glucocerebrosidase , 2007, Cell.

[161]  Min Zhu,et al.  GM1 Specifically Interacts with α-Synuclein and Inhibits Fibrillation† , 2007 .

[162]  A. Cuervo,et al.  Lysosome membrane lipid microdomains: novel regulators of chaperone‐mediated autophagy , 2006, The EMBO journal.

[163]  Masaaki Komatsu,et al.  Loss of autophagy in the central nervous system causes neurodegeneration in mice , 2006, Nature.

[164]  Hideyuki Okano,et al.  Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice , 2006, Nature.

[165]  F. Kamp,et al.  Binding of α-Synuclein Affects the Lipid Packing in Bilayers of Small Vesicles* , 2006, Journal of Biological Chemistry.

[166]  Mario Maas,et al.  Substrate reduction therapy of glycosphingolipid storage disorders , 2006, Journal of Inherited Metabolic Disease.

[167]  F. Felicetti,et al.  The N370S (Asn370-->Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C. , 2005, The Biochemical journal.

[168]  Ad Bax,et al.  Structure and Dynamics of Micelle-bound Human α-Synuclein* , 2005, Journal of Biological Chemistry.

[169]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[170]  M. Herkenham,et al.  Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3 , 2003, Neurobiology of Disease.

[171]  J. Sussman,et al.  X‐ray structure of human acid‐β‐glucosidase, the defective enzyme in Gaucher disease , 2003, EMBO reports.

[172]  R. Dwek,et al.  Glucosylceramide modulates membrane traffic along the endocytic pathway Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200232-JLR200 , 2002, Journal of Lipid Research.

[173]  Hansjürgen Bratzke,et al.  Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) , 2002, Journal of Neurology.

[174]  T. Linke,et al.  Lysosomal Degradation on Vesicular Membrane Surfaces , 1998, The Journal of Biological Chemistry.

[175]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[176]  A. Cuervo,et al.  A Receptor for the Selective Uptake and Degradation of Proteins by Lysosomes , 1996, Science.

[177]  I. Goto,et al.  The synthetic pathway for glucosylsphingosine in cultured fibroblasts. , 1994, Journal of biochemistry.

[178]  C. Tanner Epidemiology of Parkinson’s Disease , 1992, Neurologic Clinics.

[179]  S. Freundlieb,et al.  A selective pathway for degradation of cytosolic proteins by lysosomes. , 1990, Seminars in cell biology.

[180]  J. Barranger,et al.  Conditions affecting the activity of glucocerebrosidase purified from spleens of control subjects and patients with type 1 Gaucher disease. , 1990, Biochimica et biophysica acta.

[181]  O. Reiner,et al.  The human glucocerebrosidase gene and pseudogene: structure and evolution. , 1989, Genomics.

[182]  R. Brady,et al.  THE METABOLISM OF GLUCOCEREBROSIDES. I. PURIFICATION AND PROPERTIES OF A GLUCOCEREBROSIDE-CLEAVING ENZYME FROM SPLEEN TISSUE. , 1965, The Journal of biological chemistry.